Tositumomab and iodine I 131 tositumomab (Bexaar)

A Srinivasan; S K Mukherji

doi:10.3174/ajnr.A2593

Tositumomab and iodine I 131 tositumomab (Bexaar)

AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8. doi: 10.3174/ajnr.A2593. Epub 2011 Mar 24.

Authors

A Srinivasan¹, S K Mukherji

Affiliation

¹ Department of Radiology, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA. ashoks@med.umich.edu

Abstract

Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Humans
Lymphoma, Non-Hodgkin / diagnostic imaging
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / radiotherapy*
Radioimmunotherapy*
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal
Antineoplastic Agents
tositumomab I-131